Diagnostic and prognostic value of human prion detection in cerebrospinal fluid

Objective Several prion amplification systems have been proposed for detection of prions in cerebrospinal fluid (CSF), most recently, the measurements of prion seeding activity with second‐generation real‐time quaking‐induced conversion (RT‐QuIC). The objective of this study was to investigate the d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of neurology 2017-01, Vol.81 (1), p.79-92
Hauptverfasser: Foutz, Aaron, Appleby, Brian S., Hamlin, Clive, Liu, Xiaoqin, Yang, Sheng, Cohen, Yvonne, Chen, Wei, Blevins, Janis, Fausett, Cameron, Wang, Han, Gambetti, Pierluigi, Zhang, Shulin, Hughson, Andrew, Tatsuoka, Curtis, Schonberger, Lawrence B., Cohen, Mark L., Caughey, Byron, Safar, Jiri G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 92
container_issue 1
container_start_page 79
container_title Annals of neurology
container_volume 81
creator Foutz, Aaron
Appleby, Brian S.
Hamlin, Clive
Liu, Xiaoqin
Yang, Sheng
Cohen, Yvonne
Chen, Wei
Blevins, Janis
Fausett, Cameron
Wang, Han
Gambetti, Pierluigi
Zhang, Shulin
Hughson, Andrew
Tatsuoka, Curtis
Schonberger, Lawrence B.
Cohen, Mark L.
Caughey, Byron
Safar, Jiri G.
description Objective Several prion amplification systems have been proposed for detection of prions in cerebrospinal fluid (CSF), most recently, the measurements of prion seeding activity with second‐generation real‐time quaking‐induced conversion (RT‐QuIC). The objective of this study was to investigate the diagnostic performance of the RT‐QuIC prion test in the broad phenotypic spectrum of prion diseases. Methods We performed CSF RT‐QuIC testing in 2,141 patients who had rapidly progressive neurological disorders, determined diagnostic sensitivity and specificity in 272 cases that were autopsied, and evaluated the impact of mutations and polymorphisms in the PRNP gene, and type 1 or type 2 human prions on diagnostic performance. Results The 98.5% diagnostic specificity and 92% sensitivity of CSF RT‐QuIC in a blinded retrospective analysis matched the 100% specificity and 95% sensitivity of a blind prospective study. The CSF RT‐QuIC differentiated 94% of cases of sporadic Creutzfeldt–Jakob disease (sCJD) MM1 from the sCJD MM2 phenotype, and 80% of sCJD VV2 from sCJD VV1. The mixed prion type 1‐2 and cases heterozygous for codon 129 generated intermediate CSF RT‐QuIC patterns, whereas genetic prion diseases revealed distinct profiles for each PRNP gene mutation. Interpretation The diagnostic performance of the improved CSF RT‐QuIC is superior to surrogate marker tests for prion diseases such as 14‐3‐3 and tau proteins, and together with PRNP gene sequencing the test allows the major prion subtypes to be differentiated in vivo. This differentiation facilitates prediction of the clinicopathological phenotype and duration of the disease—two important considerations for envisioned therapeutic interventions. ANN NEUROL 2017;81:79–92
doi_str_mv 10.1002/ana.24833
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5266667</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1844355603</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5703-c2384449fba1755a925540f0211d475f40cd7ccb00f7c8befddb3dd0a10071b83</originalsourceid><addsrcrecordid>eNqNkV1rFTEQhoNY7LF64R-QBW_0YtuZfG1yIxxav6DYG70O2STbpuxJjpvdSv99U09bVLA4N5kwDy8z70vIK4RDBKBHNtlDyhVjT8gKBcNWUa6fkhUwyVuBjO-T56VcAoCWCM_IPu2UZij5ipydRHuecpmja2zyzXbK998rOy6hyUNzsWxsqpOYU-PDHNx828XUuDCFfsplG5Mdm2Fcon9B9gY7lvDy7j0g3z9--Hb8uT09-_TleH3aOtEBax1linOuh95iJ4TVVAgOA1BEzzsxcHC-c64HGDqn-jB43zPvwdZ7O-wVOyDvd7rbpd8E70KaJzuauuTGTtcm22j-nKR4Yc7zlRFU1uqqwNs7gSn_WEKZzSYWF8bRppCXYlBJxZArrv4D5ZwJIYFV9M1f6GVepupOpbTWiEClepRSEimTQmOl3u0oVy0uUxgerkMwt7mbmrv5lXtlX_9uxwN5H3QFjnbAzziG638rmfXX9U7yBm_utkI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1861236591</pqid></control><display><type>article</type><title>Diagnostic and prognostic value of human prion detection in cerebrospinal fluid</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Foutz, Aaron ; Appleby, Brian S. ; Hamlin, Clive ; Liu, Xiaoqin ; Yang, Sheng ; Cohen, Yvonne ; Chen, Wei ; Blevins, Janis ; Fausett, Cameron ; Wang, Han ; Gambetti, Pierluigi ; Zhang, Shulin ; Hughson, Andrew ; Tatsuoka, Curtis ; Schonberger, Lawrence B. ; Cohen, Mark L. ; Caughey, Byron ; Safar, Jiri G.</creator><creatorcontrib>Foutz, Aaron ; Appleby, Brian S. ; Hamlin, Clive ; Liu, Xiaoqin ; Yang, Sheng ; Cohen, Yvonne ; Chen, Wei ; Blevins, Janis ; Fausett, Cameron ; Wang, Han ; Gambetti, Pierluigi ; Zhang, Shulin ; Hughson, Andrew ; Tatsuoka, Curtis ; Schonberger, Lawrence B. ; Cohen, Mark L. ; Caughey, Byron ; Safar, Jiri G.</creatorcontrib><description>Objective Several prion amplification systems have been proposed for detection of prions in cerebrospinal fluid (CSF), most recently, the measurements of prion seeding activity with second‐generation real‐time quaking‐induced conversion (RT‐QuIC). The objective of this study was to investigate the diagnostic performance of the RT‐QuIC prion test in the broad phenotypic spectrum of prion diseases. Methods We performed CSF RT‐QuIC testing in 2,141 patients who had rapidly progressive neurological disorders, determined diagnostic sensitivity and specificity in 272 cases that were autopsied, and evaluated the impact of mutations and polymorphisms in the PRNP gene, and type 1 or type 2 human prions on diagnostic performance. Results The 98.5% diagnostic specificity and 92% sensitivity of CSF RT‐QuIC in a blinded retrospective analysis matched the 100% specificity and 95% sensitivity of a blind prospective study. The CSF RT‐QuIC differentiated 94% of cases of sporadic Creutzfeldt–Jakob disease (sCJD) MM1 from the sCJD MM2 phenotype, and 80% of sCJD VV2 from sCJD VV1. The mixed prion type 1‐2 and cases heterozygous for codon 129 generated intermediate CSF RT‐QuIC patterns, whereas genetic prion diseases revealed distinct profiles for each PRNP gene mutation. Interpretation The diagnostic performance of the improved CSF RT‐QuIC is superior to surrogate marker tests for prion diseases such as 14‐3‐3 and tau proteins, and together with PRNP gene sequencing the test allows the major prion subtypes to be differentiated in vivo. This differentiation facilitates prediction of the clinicopathological phenotype and duration of the disease—two important considerations for envisioned therapeutic interventions. ANN NEUROL 2017;81:79–92</description><identifier>ISSN: 0364-5134</identifier><identifier>EISSN: 1531-8249</identifier><identifier>DOI: 10.1002/ana.24833</identifier><identifier>PMID: 27893164</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>14-3-3 protein ; Aged ; Autopsies ; Biomarkers ; Case-Control Studies ; Cerebrospinal fluid ; Creutzfeldt-Jakob disease ; Diagnostic systems ; Female ; Gene sequencing ; Human performance ; Humans ; In vivo methods and tests ; Male ; Middle Aged ; Mutation ; Neurological diseases ; Phenotypes ; Point mutation ; Predictive Value of Tests ; Prion Diseases - cerebrospinal fluid ; Prion Diseases - diagnosis ; Prion Diseases - genetics ; Prion protein ; Prion Proteins - cerebrospinal fluid ; Prion Proteins - genetics ; Prions ; Prognosis ; Protein seeding ; Proteins ; Sensitivity ; Sensitivity analysis ; Sensitivity and Specificity ; Tau protein ; Therapeutic applications</subject><ispartof>Annals of neurology, 2017-01, Vol.81 (1), p.79-92</ispartof><rights>2016 American Neurological Association</rights><rights>2016 American Neurological Association.</rights><rights>2017 American Neurological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5703-c2384449fba1755a925540f0211d475f40cd7ccb00f7c8befddb3dd0a10071b83</citedby><cites>FETCH-LOGICAL-c5703-c2384449fba1755a925540f0211d475f40cd7ccb00f7c8befddb3dd0a10071b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fana.24833$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fana.24833$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27893164$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Foutz, Aaron</creatorcontrib><creatorcontrib>Appleby, Brian S.</creatorcontrib><creatorcontrib>Hamlin, Clive</creatorcontrib><creatorcontrib>Liu, Xiaoqin</creatorcontrib><creatorcontrib>Yang, Sheng</creatorcontrib><creatorcontrib>Cohen, Yvonne</creatorcontrib><creatorcontrib>Chen, Wei</creatorcontrib><creatorcontrib>Blevins, Janis</creatorcontrib><creatorcontrib>Fausett, Cameron</creatorcontrib><creatorcontrib>Wang, Han</creatorcontrib><creatorcontrib>Gambetti, Pierluigi</creatorcontrib><creatorcontrib>Zhang, Shulin</creatorcontrib><creatorcontrib>Hughson, Andrew</creatorcontrib><creatorcontrib>Tatsuoka, Curtis</creatorcontrib><creatorcontrib>Schonberger, Lawrence B.</creatorcontrib><creatorcontrib>Cohen, Mark L.</creatorcontrib><creatorcontrib>Caughey, Byron</creatorcontrib><creatorcontrib>Safar, Jiri G.</creatorcontrib><title>Diagnostic and prognostic value of human prion detection in cerebrospinal fluid</title><title>Annals of neurology</title><addtitle>Ann Neurol</addtitle><description>Objective Several prion amplification systems have been proposed for detection of prions in cerebrospinal fluid (CSF), most recently, the measurements of prion seeding activity with second‐generation real‐time quaking‐induced conversion (RT‐QuIC). The objective of this study was to investigate the diagnostic performance of the RT‐QuIC prion test in the broad phenotypic spectrum of prion diseases. Methods We performed CSF RT‐QuIC testing in 2,141 patients who had rapidly progressive neurological disorders, determined diagnostic sensitivity and specificity in 272 cases that were autopsied, and evaluated the impact of mutations and polymorphisms in the PRNP gene, and type 1 or type 2 human prions on diagnostic performance. Results The 98.5% diagnostic specificity and 92% sensitivity of CSF RT‐QuIC in a blinded retrospective analysis matched the 100% specificity and 95% sensitivity of a blind prospective study. The CSF RT‐QuIC differentiated 94% of cases of sporadic Creutzfeldt–Jakob disease (sCJD) MM1 from the sCJD MM2 phenotype, and 80% of sCJD VV2 from sCJD VV1. The mixed prion type 1‐2 and cases heterozygous for codon 129 generated intermediate CSF RT‐QuIC patterns, whereas genetic prion diseases revealed distinct profiles for each PRNP gene mutation. Interpretation The diagnostic performance of the improved CSF RT‐QuIC is superior to surrogate marker tests for prion diseases such as 14‐3‐3 and tau proteins, and together with PRNP gene sequencing the test allows the major prion subtypes to be differentiated in vivo. This differentiation facilitates prediction of the clinicopathological phenotype and duration of the disease—two important considerations for envisioned therapeutic interventions. ANN NEUROL 2017;81:79–92</description><subject>14-3-3 protein</subject><subject>Aged</subject><subject>Autopsies</subject><subject>Biomarkers</subject><subject>Case-Control Studies</subject><subject>Cerebrospinal fluid</subject><subject>Creutzfeldt-Jakob disease</subject><subject>Diagnostic systems</subject><subject>Female</subject><subject>Gene sequencing</subject><subject>Human performance</subject><subject>Humans</subject><subject>In vivo methods and tests</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Neurological diseases</subject><subject>Phenotypes</subject><subject>Point mutation</subject><subject>Predictive Value of Tests</subject><subject>Prion Diseases - cerebrospinal fluid</subject><subject>Prion Diseases - diagnosis</subject><subject>Prion Diseases - genetics</subject><subject>Prion protein</subject><subject>Prion Proteins - cerebrospinal fluid</subject><subject>Prion Proteins - genetics</subject><subject>Prions</subject><subject>Prognosis</subject><subject>Protein seeding</subject><subject>Proteins</subject><subject>Sensitivity</subject><subject>Sensitivity analysis</subject><subject>Sensitivity and Specificity</subject><subject>Tau protein</subject><subject>Therapeutic applications</subject><issn>0364-5134</issn><issn>1531-8249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV1rFTEQhoNY7LF64R-QBW_0YtuZfG1yIxxav6DYG70O2STbpuxJjpvdSv99U09bVLA4N5kwDy8z70vIK4RDBKBHNtlDyhVjT8gKBcNWUa6fkhUwyVuBjO-T56VcAoCWCM_IPu2UZij5ipydRHuecpmja2zyzXbK998rOy6hyUNzsWxsqpOYU-PDHNx828XUuDCFfsplG5Mdm2Fcon9B9gY7lvDy7j0g3z9--Hb8uT09-_TleH3aOtEBax1linOuh95iJ4TVVAgOA1BEzzsxcHC-c64HGDqn-jB43zPvwdZ7O-wVOyDvd7rbpd8E70KaJzuauuTGTtcm22j-nKR4Yc7zlRFU1uqqwNs7gSn_WEKZzSYWF8bRppCXYlBJxZArrv4D5ZwJIYFV9M1f6GVepupOpbTWiEClepRSEimTQmOl3u0oVy0uUxgerkMwt7mbmrv5lXtlX_9uxwN5H3QFjnbAzziG638rmfXX9U7yBm_utkI</recordid><startdate>201701</startdate><enddate>201701</enddate><creator>Foutz, Aaron</creator><creator>Appleby, Brian S.</creator><creator>Hamlin, Clive</creator><creator>Liu, Xiaoqin</creator><creator>Yang, Sheng</creator><creator>Cohen, Yvonne</creator><creator>Chen, Wei</creator><creator>Blevins, Janis</creator><creator>Fausett, Cameron</creator><creator>Wang, Han</creator><creator>Gambetti, Pierluigi</creator><creator>Zhang, Shulin</creator><creator>Hughson, Andrew</creator><creator>Tatsuoka, Curtis</creator><creator>Schonberger, Lawrence B.</creator><creator>Cohen, Mark L.</creator><creator>Caughey, Byron</creator><creator>Safar, Jiri G.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>201701</creationdate><title>Diagnostic and prognostic value of human prion detection in cerebrospinal fluid</title><author>Foutz, Aaron ; Appleby, Brian S. ; Hamlin, Clive ; Liu, Xiaoqin ; Yang, Sheng ; Cohen, Yvonne ; Chen, Wei ; Blevins, Janis ; Fausett, Cameron ; Wang, Han ; Gambetti, Pierluigi ; Zhang, Shulin ; Hughson, Andrew ; Tatsuoka, Curtis ; Schonberger, Lawrence B. ; Cohen, Mark L. ; Caughey, Byron ; Safar, Jiri G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5703-c2384449fba1755a925540f0211d475f40cd7ccb00f7c8befddb3dd0a10071b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>14-3-3 protein</topic><topic>Aged</topic><topic>Autopsies</topic><topic>Biomarkers</topic><topic>Case-Control Studies</topic><topic>Cerebrospinal fluid</topic><topic>Creutzfeldt-Jakob disease</topic><topic>Diagnostic systems</topic><topic>Female</topic><topic>Gene sequencing</topic><topic>Human performance</topic><topic>Humans</topic><topic>In vivo methods and tests</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Neurological diseases</topic><topic>Phenotypes</topic><topic>Point mutation</topic><topic>Predictive Value of Tests</topic><topic>Prion Diseases - cerebrospinal fluid</topic><topic>Prion Diseases - diagnosis</topic><topic>Prion Diseases - genetics</topic><topic>Prion protein</topic><topic>Prion Proteins - cerebrospinal fluid</topic><topic>Prion Proteins - genetics</topic><topic>Prions</topic><topic>Prognosis</topic><topic>Protein seeding</topic><topic>Proteins</topic><topic>Sensitivity</topic><topic>Sensitivity analysis</topic><topic>Sensitivity and Specificity</topic><topic>Tau protein</topic><topic>Therapeutic applications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Foutz, Aaron</creatorcontrib><creatorcontrib>Appleby, Brian S.</creatorcontrib><creatorcontrib>Hamlin, Clive</creatorcontrib><creatorcontrib>Liu, Xiaoqin</creatorcontrib><creatorcontrib>Yang, Sheng</creatorcontrib><creatorcontrib>Cohen, Yvonne</creatorcontrib><creatorcontrib>Chen, Wei</creatorcontrib><creatorcontrib>Blevins, Janis</creatorcontrib><creatorcontrib>Fausett, Cameron</creatorcontrib><creatorcontrib>Wang, Han</creatorcontrib><creatorcontrib>Gambetti, Pierluigi</creatorcontrib><creatorcontrib>Zhang, Shulin</creatorcontrib><creatorcontrib>Hughson, Andrew</creatorcontrib><creatorcontrib>Tatsuoka, Curtis</creatorcontrib><creatorcontrib>Schonberger, Lawrence B.</creatorcontrib><creatorcontrib>Cohen, Mark L.</creatorcontrib><creatorcontrib>Caughey, Byron</creatorcontrib><creatorcontrib>Safar, Jiri G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Foutz, Aaron</au><au>Appleby, Brian S.</au><au>Hamlin, Clive</au><au>Liu, Xiaoqin</au><au>Yang, Sheng</au><au>Cohen, Yvonne</au><au>Chen, Wei</au><au>Blevins, Janis</au><au>Fausett, Cameron</au><au>Wang, Han</au><au>Gambetti, Pierluigi</au><au>Zhang, Shulin</au><au>Hughson, Andrew</au><au>Tatsuoka, Curtis</au><au>Schonberger, Lawrence B.</au><au>Cohen, Mark L.</au><au>Caughey, Byron</au><au>Safar, Jiri G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic and prognostic value of human prion detection in cerebrospinal fluid</atitle><jtitle>Annals of neurology</jtitle><addtitle>Ann Neurol</addtitle><date>2017-01</date><risdate>2017</risdate><volume>81</volume><issue>1</issue><spage>79</spage><epage>92</epage><pages>79-92</pages><issn>0364-5134</issn><eissn>1531-8249</eissn><abstract>Objective Several prion amplification systems have been proposed for detection of prions in cerebrospinal fluid (CSF), most recently, the measurements of prion seeding activity with second‐generation real‐time quaking‐induced conversion (RT‐QuIC). The objective of this study was to investigate the diagnostic performance of the RT‐QuIC prion test in the broad phenotypic spectrum of prion diseases. Methods We performed CSF RT‐QuIC testing in 2,141 patients who had rapidly progressive neurological disorders, determined diagnostic sensitivity and specificity in 272 cases that were autopsied, and evaluated the impact of mutations and polymorphisms in the PRNP gene, and type 1 or type 2 human prions on diagnostic performance. Results The 98.5% diagnostic specificity and 92% sensitivity of CSF RT‐QuIC in a blinded retrospective analysis matched the 100% specificity and 95% sensitivity of a blind prospective study. The CSF RT‐QuIC differentiated 94% of cases of sporadic Creutzfeldt–Jakob disease (sCJD) MM1 from the sCJD MM2 phenotype, and 80% of sCJD VV2 from sCJD VV1. The mixed prion type 1‐2 and cases heterozygous for codon 129 generated intermediate CSF RT‐QuIC patterns, whereas genetic prion diseases revealed distinct profiles for each PRNP gene mutation. Interpretation The diagnostic performance of the improved CSF RT‐QuIC is superior to surrogate marker tests for prion diseases such as 14‐3‐3 and tau proteins, and together with PRNP gene sequencing the test allows the major prion subtypes to be differentiated in vivo. This differentiation facilitates prediction of the clinicopathological phenotype and duration of the disease—two important considerations for envisioned therapeutic interventions. ANN NEUROL 2017;81:79–92</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27893164</pmid><doi>10.1002/ana.24833</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0364-5134
ispartof Annals of neurology, 2017-01, Vol.81 (1), p.79-92
issn 0364-5134
1531-8249
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5266667
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects 14-3-3 protein
Aged
Autopsies
Biomarkers
Case-Control Studies
Cerebrospinal fluid
Creutzfeldt-Jakob disease
Diagnostic systems
Female
Gene sequencing
Human performance
Humans
In vivo methods and tests
Male
Middle Aged
Mutation
Neurological diseases
Phenotypes
Point mutation
Predictive Value of Tests
Prion Diseases - cerebrospinal fluid
Prion Diseases - diagnosis
Prion Diseases - genetics
Prion protein
Prion Proteins - cerebrospinal fluid
Prion Proteins - genetics
Prions
Prognosis
Protein seeding
Proteins
Sensitivity
Sensitivity analysis
Sensitivity and Specificity
Tau protein
Therapeutic applications
title Diagnostic and prognostic value of human prion detection in cerebrospinal fluid
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A15%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20and%20prognostic%20value%20of%20human%20prion%20detection%20in%20cerebrospinal%20fluid&rft.jtitle=Annals%20of%20neurology&rft.au=Foutz,%20Aaron&rft.date=2017-01&rft.volume=81&rft.issue=1&rft.spage=79&rft.epage=92&rft.pages=79-92&rft.issn=0364-5134&rft.eissn=1531-8249&rft_id=info:doi/10.1002/ana.24833&rft_dat=%3Cproquest_pubme%3E1844355603%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1861236591&rft_id=info:pmid/27893164&rfr_iscdi=true